Sermorelin

Sermorelin is a synthetic peptide hormone and the shortest fully functional fragment (amino acids 1-29) of endogenous human growth hormone-releasing hormone (GHRH). As a GHRH secretagogue, it binds to receptors in the anterior pituitary and prompts the gland to release your own growth hormone (GH) in physiological pulses - rather than supplying GH directly. This fundamentally distinguishes the approach from classical recombinant hGH substitution.

How does Sermorelin work?

Sermorelin mimics endogenous GHRH and stimulates somatotropic cells of the anterior pituitary, which increases pulsatile GH release and consequently raises hepatic IGF-1. Unlike direct administration of recombinant human growth hormone (rhGH), the hypothalamic-pituitary feedback loops remain intact - your body's own regulation is not shut off.

Pharmacologically, the half-life is short - about 11-12 minutes after subcutaneous injection - and absolute bioavailability is around 6 percent. Even so, the stimulus is enough to measurably raise GH output, as demonstrated in studies on sleep-associated GH release.

What is Sermorelin used for?

Sermorelin was originally approved (under the brand name Geref) for the diagnosis and treatment of idiopathic growth hormone deficiency in children with growth failure. After the commercial discontinuation of the branded product, it is now mainly used off-label or through compounding pharmacies for:

• Suspected adult growth hormone deficiency
• Anti-aging protocols (sleep quality, recovery, body composition)
• Adjunct during dieting or recovery phases

Important: there is no currently FDA-approved Sermorelin product on the market. The manufacturer (EMD Serono) voluntarily withdrew it in 2008 for commercial reasons. In a 2013 Federal Register notice, the FDA explicitly confirmed that the withdrawal was not due to safety or effectiveness concerns.

How does Sermorelin differ from Tesamorelin?

Tesamorelin and Sermorelin are both GHRH analogs, but they differ in several ways:

• Chain length: Tesamorelin comprises 44 amino acids (GHRH 1-44); Sermorelin only 29 (GHRH 1-29).
• Regulatory status: Tesamorelin (Egrifta) is currently FDA-approved for HIV-associated lipodystrophy; Sermorelin's branded product was discontinued and is only available as a compounded preparation.
• Indication: Tesamorelin has a concrete approved indication; Sermorelin is used off-label for GHD diagnostics and anti-aging concepts.

For a broader side-by-side view see the comparison sections on Peptipedia.

Dosage and administration

The commonly reported subcutaneous dose in the literature and compounding protocols ranges from roughly 200-500 µg once daily, usually at bedtime to mimic the natural nocturnal GH peak. This is not a dosage recommendation - any use belongs in medical hands and is individualized based on IGF-1 levels and clinical picture.

Side effects and safety

Most commonly reported effects are injection-site reactions, flushing, headache, and occasionally nausea. Because Sermorelin acts via the body's own GH axis, severe adverse effects are rare as long as contraindications (active malignancy, severe sleep apnea, uncontrolled diabetes) are respected. Long-term data from large modern trials are, however, limited.

Current status

Sermorelin occupies a special niche: it once had FDA approval, but the sponsor voluntarily withdrew the NDA in 2008 for commercial reasons (rhGH had come to dominate the pediatric GHD market). It is therefore mainly available today through 503A compounding pharmacies. For evidence-based information on CJC-1295 / Ipamorelin or Tesamorelin, you can find dedicated entries on Peptipedia.